A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
J HardyP Curtis

Abstract

Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients. The aim of this study was to compare the anti-emetic efficacy and safety of ondansetron, placebo and metoclopramide in the treatment of opioid-induced nausea and emesis (OIE) in cancer patients. This was a multinational, multicentre, double-blind, parallel group study in which cancer patients who were receiving a full opioid agonist for cancer pain were randomised to receive one of oral ondansetron 24 mg once daily, metoclopramide 10 mg three times daily, or placebo. Study medication was started only if the patient experienced nausea and/or emesis following opioid administration. Efficacy and safety assessments were made over a study period of 24 h from the time of the first dose of anti-emetics/placebo. The study was terminated prematurely because of the difficulties in recruiting patients satisfying the stringent entry criteria. Ninety-two patients were included in the intent-to-treat population: 30 patients received placebo, 29 patients ondansetron and 33 patients metoclopramide. There was no statistically significant difference between the groups in the proportion achieving complete control of emesis (33% of patients o...Continue Reading

Citations

Sep 8, 2010·Journal of Feline Medicine and Surgery·Saeed Kolahian, Seyedhosein Jarolmasjed
Apr 25, 2006·Journal of Palliative Medicine·Shalini DalalEduardo Bruera
Oct 5, 2010·British Medical Bulletin·Dylan G Harris
Oct 4, 2011·Clinical Interventions in Aging·Paul GlareRoma Tickoo
Nov 12, 2013·European Journal of Pharmacology·Pamela GordonDeclan Walsh
Jan 1, 2008·Journal of Pain & Palliative Care Pharmacotherapy·Ewan McNicol
Mar 24, 2009·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Frank Porreca, Michael H Ossipov
Apr 24, 2010·Journal of Pain and Symptom Management·Mellar P DavisUNKNOWN Palliative Medicine Study Group of the Multinational Association of Supportive Care in Cancer
May 24, 2006·Journal of Pain and Symptom Management·Lea Renina LlanesSharon Watanabe
Apr 22, 2015·Journal of Pain and Symptom Management·Geoffrey K MitchellDavid C Currow
Nov 4, 2016·Current Treatment Options in Gastroenterology·Allen A Lee, William L Hasler
Mar 4, 2010·The American Journal of Hospice & Palliative Care·Sik Kim AngMellar P Davis
Aug 16, 2011·International Journal of Palliative Nursing·Kathryn Hamling
Jun 25, 2008·The American Journal of Hospice & Palliative Care·Geetika KumarRosemary Clark
Dec 5, 2002·Pharmacoepidemiology and Drug Safety
Sep 22, 2018·Journal of Palliative Medicine·Tonje A SandeMarie T Fallon
Dec 20, 2008·Drugs·Paul A GlareJanet R Hardy
Oct 31, 2015·Journal of Palliative Care·Korana Kindl, Phillip Good
Aug 19, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Declan WalshAlex Molassiotis
Jan 27, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Raffaele GiustiLucilla Verna
Jan 15, 2021·Current Treatment Options in Oncology·Janet Hardy, Mellar P Davis
Aug 17, 2021·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mellar DavisEduardo Bruera

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.